| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 03/03/2004 | EP1392326A1 Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators |
| 03/03/2004 | EP1392319A2 Hypotensive lipid (prostaglandin) and timolol compositions and methods of using same |
| 03/03/2004 | EP1392315A1 Methods of treating alzheimer's disease |
| 03/03/2004 | EP1392314A1 Novel use of 2-phenyl-substituted imidazotriazinones |
| 03/03/2004 | EP1392313A1 Combination comprising n- 5- 4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl -4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent |
| 03/03/2004 | EP1392312A1 TRIAZOLO 4,5-d] PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS |
| 03/03/2004 | EP1392310A1 Combinations of aldose reductase inhibitors and cyclooxygenase-2 inhibitors |
| 03/03/2004 | EP1392308A1 Alpha-2-adrenergic agonist/fatty acid compositions |
| 03/03/2004 | EP1392305A2 Methods for treating neurodegenerative diseases including alzheimer's |
| 03/03/2004 | EP1392301A2 Prevention of addiction in pain management |
| 03/03/2004 | EP1392294A1 7,8-fused 4$i(h)-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 03/03/2004 | EP1392288A2 Medicament containing an effector of the glutathione metabolism together with $g(a)-lipoic acid for treating diabetes mellitus |
| 03/03/2004 | EP1392286A2 Antineoplastic combinations |
| 03/03/2004 | EP1392285A1 Medicament containing an effector of the glutathione metabolism together with alpha-lipoic acid for use in kidney replacement therapy |
| 03/03/2004 | EP1392284A2 Methods of treating hyperlipidemia |
| 03/03/2004 | EP1392279A1 Trimethyl lock based tetrapartate prodrugs |
| 03/03/2004 | EP1392278A1 Production and use of a polar lipid-rich fraction containing stearidonic acid and gamma linolenic acid from plant seeds and microbes |
| 03/03/2004 | EP1392276A1 Potentiation of therapeutic effects of polyunsaturated fatty acids |
| 03/03/2004 | EP1392273A1 Novel treatment for obsessive-compulsive disorder (ocd) and ocd-related disorders using gvg |
| 03/03/2004 | EP1392272A1 Permeation enhancers |
| 03/03/2004 | EP1392271A1 Swallow tablet comprising paracetamol |
| 03/03/2004 | EP1392270A2 Abuse resistant pharmaceutical composition containing capsaicin |
| 03/03/2004 | EP1392265A2 Inhibitors of abc drug transporters at the blood-brain barrier |
| 03/03/2004 | EP1392264A1 Delivery of antiemetics through an inhalation route |
| 03/03/2004 | EP1392262A1 Delivery of drug esters through an inhalation route |
| 03/03/2004 | EP1392261A2 Delivery of nonsteroidal antiinflammatory drugs through an inhalation route |
| 03/03/2004 | EP1392259A2 Delivery of erectile dysfunction drugs through an inhalation route |
| 03/03/2004 | EP1392257A1 Delivery of antihistamines through an inhalation route |
| 03/03/2004 | EP1392247A2 Process for preparing granular compositions |
| 03/03/2004 | EP1392243A2 Topical composition with a lamellar double-membrane structure, containing a n-acyl-ethanolamine and/or a quaternary ammonium salt and/or an adenosylmethionine |
| 03/03/2004 | EP1259128A4 Water containing soluble fiber |
| 03/03/2004 | EP1210345B1 Oxazole ppar antagonists |
| 03/03/2004 | EP1202717B1 Use of naaladase inhibitors for treating anxiety and memory disorders |
| 03/03/2004 | EP1169064B1 Method of detecting endometriosis |
| 03/03/2004 | EP1140020B1 Large molecule drug delivery system using aerosolized membrane-mimetic amphiphiles |
| 03/03/2004 | EP1109571B1 Methods of treating salt-dependent hypertension |
| 03/03/2004 | EP1037655B1 use of novel ligands of the neuropeptide receptor hfgan72 and antagonists thereof in therapy |
| 03/03/2004 | EP0865290B1 Pharmaceutical compositions for oral use including an nsaid and ceramides |
| 03/03/2004 | EP0839033B1 Use of l-carnitine and derivatives for reducing ceramide levels and potentiating antiretroviral |
| 03/03/2004 | CN1479872A Materials and methods to modulate ligand binding/enzymatic activity of alpha/beta proteins containing allosteric regulatory site |
| 03/03/2004 | CN1479871A Diagnostic and theraputic methods based on L1 adhesion molecule for ovarian and endometrial tumors |
| 03/03/2004 | CN1479747A Methylene steroids as novel androgens |
| 03/03/2004 | CN1479734A Arylated furane and thenoyl amine with potassium channel blocking effect |
| 03/03/2004 | CN1479654A Method for coating high-efficient ingredient on partial or complete in implants and on plants |
| 03/03/2004 | CN1479638A Improvement of graft acceptance through manipulation of thymic regeneration |
| 03/03/2004 | CN1479630A Method of inducing cancer cell death and tumor regression |
| 03/03/2004 | CN1479629A Combinations and compositions which interfere with VEGF/VEFG and anglopoietin/Tie receptor function and their use (II) |
| 03/03/2004 | CN1479628A Use of CYP206 inhibitors in combination therapies |
| 03/03/2004 | CN1479621A Treatment of urindry dysfunction |
| 03/03/2004 | CN1479618A Treatment of sexual dysfunction using boonbesin antagonist |
| 03/03/2004 | CN1479616A Therapy for herpes neurological viral conditions utilizing 1,4-dihydropyridine calcium channel blockers |
| 03/03/2004 | CN1479613A Rapidly disintegrating tablet comprising acid-sensitive active ingredient |
| 03/03/2004 | CN1478472A 细胞粘连抑制剂 Cell adhesion inhibitor |
| 03/03/2004 | CN1140536C Minotopes and anti-mimotopes of human platelet glycoprotein Ib/Ix |
| 03/03/2004 | CN1140264C Chewing gum containing colloidal bismuth subcitrate |
| 03/02/2004 | US6700018 3-hydroxy-2-(2-naphthyl)pentylamine derivatives |
| 03/02/2004 | US6699965 Used for as a drug screening target; protein from rat and human brains |
| 03/02/2004 | US6699908 Methods for providing safe local anesthesia |
| 03/02/2004 | US6699904 PPAR agonists |
| 03/02/2004 | US6699885 Substituted benzimidazole dosage forms and methods of using same |
| 03/02/2004 | US6699871 Such as 7-((3r)-3-amino-4-(3,4-difluorophenyl)butanoyl)-2-(trifluoromethyl)-5,6,7,8 -tetrahydroimidazo(1,2-a)pyrazine dihydrochloride for treatment of insulin resistance disorders |
| 03/02/2004 | US6699865 Protein kinase inhibitors, for treating cancer inflammatory disorders, restenosis, and cardiovascular disease. |
| 03/02/2004 | US6699832 May contain another compound to treat diabetes, sexual dysfunction, atherosclerosis, insulin resistance, impaired glucose tolerance, hypercholesterolemia or hypertriglyceridemia |
| 03/02/2004 | US6699716 In vivo induction for enhanced function of isolated hepatocytes |
| 03/02/2004 | US6699677 Identifying a ligand-orphan receptor interaction by use of immobilized tethered ligand fusion proteins having a ligand domain, a stalk domain, and optionally an immobilization domain; drug screening, diagnosis |
| 03/02/2004 | US6699504 Drug delivery |
| 03/02/2004 | US6699493 Performing the transplant, and implanting in the eye a biodegradable drug delivery system comprising an immunosuppressant and a biodegradable polymer |
| 03/02/2004 | US6699473 Human anti-epidermal growth factor receptor single-chain antibodies |
| 03/02/2004 | US6699471 Biocompatible composition in the form of a gel for use in the treatment of, inflammation,tumors and bone disorders |
| 03/02/2004 | US6699467 As carriers for delivering active agents such as peptides, drugs by administration, such as oral, subcutaneous, sublingual, and intranasal administration |
| 03/02/2004 | CA2259449C Treatment of sepsis-induced acute renal failure and renal vasoconstriction and catecholamine-induced renal and mesenteric vasoconstriction |
| 03/02/2004 | CA2232879C Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
| 02/26/2004 | WO2004016726A2 Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| 02/26/2004 | WO2004016601A1 Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity |
| 02/26/2004 | WO2004016275A1 Separate type medical material |
| 02/26/2004 | WO2004016272A1 Use of reboxetine for the treatment of hot flashes |
| 02/26/2004 | WO2004016258A1 Therapeutical use of guanylhydrazones for treating diseases associated with dendritic cell maturation |
| 02/26/2004 | WO2004016256A2 AGONISM OF THE 5HT2a RECEPTOR FOR TREATMENT OF THERMOREGULATORY DYSFUNCTION |
| 02/26/2004 | WO2004016253A1 Use of nf-kappa b inhibitors for the treatment of mastitis |
| 02/26/2004 | WO2004016244A2 Pharmaceutical compositions for buccal delivery of pain relief medications |
| 02/26/2004 | WO2004016243A2 Methods of administering and enhancing absorption of pharmaceutical agents |
| 02/26/2004 | WO2004016221A2 Sulfonamides as potassium channel blockers |
| 02/26/2004 | WO2004016100A2 Nutritional supplement for adolescents |
| 02/26/2004 | WO2004004763A3 Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair |
| 02/26/2004 | WO2004002423A3 Cartilage enhancing food supplements with sucralose and methods of preparing the same |
| 02/26/2004 | WO2004000237A3 Enhancing treatment of mdr cancer with adenosine a3 antagonists |
| 02/26/2004 | WO2003099337A3 Inclusion complexes of rosiglitazone |
| 02/26/2004 | WO2003099211A3 Mitotic kinesin inhibitors |
| 02/26/2004 | WO2003099203A3 Enteric coated caffeine tablet |
| 02/26/2004 | WO2003098223A3 A method for killing cells by inhibiting histone activity in the cell |
| 02/26/2004 | WO2003091387A9 Non-invasive delivery of polypeptides through the blood-brain barrier, and in vivo selection of endocytotic ligands |
| 02/26/2004 | WO2003088985A3 Use of compositions containing petasites for treating diseases |
| 02/26/2004 | WO2003087841A3 An ephrin-b receptor protein involved in carcinoma |
| 02/26/2004 | WO2003087345A3 Stimulation of nerve cell regeneration |
| 02/26/2004 | WO2003087333A3 Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| 02/26/2004 | WO2003083050A3 Human deubiquitinating protease gene on chromosome 7 and its murine ortholog |
| 02/26/2004 | WO2003079978A3 Protease activity of thrombin inhibits angiogenesis |
| 02/26/2004 | WO2003070234A9 Alkylating agent combinations in the treatment of cancer |
| 02/26/2004 | WO2003068156A3 Methods for treating or inhibiting sick building syndrome, post-lyme disease syndrome, and/or chronic fatigue syndrome |
| 02/26/2004 | WO2003066813A3 MINRs AS MODIFIERS OF INSULIN RECEPTOR SIGNALING AND METHODS OF USE |